Takeda has chosen leon-nanodrugs' proprietary MicroJet Reactor (MJR) nano-technology for a feasibility assessment that could potentially lead to the development of an innovative formulation of one of their current pipeline products.

leon-nanodrugs said it started a feasibility assessment collaboration with Takeda under which it will support Takeda's formulation efforts to optimize solubility, bioavailability and stability for one of Takeda's current pipeline products for drug delivery using the MJR platform.

leon`s platform can be used from early compound screening to production of market batches. Positive results from this feasibility study could potentially result in a long-term collaboration between the companies, and additional compounds may also be considered.

It is estimated that over 60% of pharmaceutical API's are poorly soluble in water. leon's MJR technology is designed to offer reformulation options that not only address this issue, but can also lead to a superior profile for the API by increasing bioavailability, reducing inter patient variability, improving onset of action, etc. The one-step, bottom up, continuous precipitation process approach of the MJR® technology is cost effective and easily scalable.

"We are very pleased and proud that Takeda selected our MJR technology for a feasibility assessment with one of their compounds in development," said Michael Mehler, chief executive officer, leon-nanodrugs GmbH. "It is a major milestone for our company to win Takeda, a globally leading pharmaceutical company, as a partner and we look forward to this collaboration with the goal to contributing to bring valuable new medicines to patients worldwide."